Published on : Aug 16, 2017
Albany, New York, August 16, 2017: The global prevalence of H. pylori infection is estimated at 50%, and 10-20% of infected adults develop peptic ulcer disease. In addition, H. pylori infection is associated with a significantly increased risk of gastric cancer, which kills more than 700,000 people each year. As a result, new treatments with activity against drug-resistant H. pylori are urgently needed. Market Research Hub (MRH) has freshly broadcasted a study to its wide repository which provides deep overview of the disease and in depth research related to Helicobacter Pylori Infections for the 7 major markets. The research is titled as “Helicobacter Pylori Infections-Market Insights, Epidemiology and Market Forecast-2025” which also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products.
At first, the report begins with a precise market outlook of helicobacter pylori infections, along with its pathophysiology, symptoms, diagnosis, staging and treatments. Helicobacter pylori (H. pylori) is a form of bacteria that causes infection in the stomach. It is found in about two-thirds of the world's population. Most of the H. pylori infections are harmless, but these bacteria are also responsible for most of the stomach ulcers and small intestine infections. Most individuals infected with H. pylori have few or no symptoms. In this study, the report further analyzes overall patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Helicobacter Pylori Infections. As per the key findings, the forecasted patient population of Helicobacter Pylori Infections for the year 2025 will grow at an impressive pace.
Additionally, the report majorly throws lights on epidemiology and patient Population; treatment algorithm, marketed drugs for Helicobacter Pylori Infection. The precise epidemiology of H. pylori infection still remains unclear; however, studies have shown that ingestion of contaminated food may increase the risk of H. pylori infection. This is an important section of the report which enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Helicobacter Pylori Infections for 7 major markets which are United States, Germany, France, Italy, Spain, U.K. and Japan. Market size for these regions is also covered in the report for the period of 2015 to 2025. According to the report, the Helicobacter Pylori Infections 7MM market size is estimated to generate substantial revenue by 2025.
The chapters including marketed products highlight the advantages and disadvantages associated with therapies associated with Helicobacter Pylori Infections, providing an in-depth analysis of emerging therapies which will create an impact through their launch. Recent studies have linked H. pylori infection with an increased risk of developing certain stomach cancer, therefore proper treatment is important. H. pylori infection requires antibiotic therapy that includes 10-14 days treatment regimen. This treatment regimen comprises of one or two antibiotics such as amoxicillin, tetracycline, metronidazole, or clarithromycin in combination with ranitidine bismuth citrate, bismuth subsalicylate, and a proton pump inhibitor (PPI).
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1265802
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org